Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

December 12, 2021

Study Completion Date

December 14, 2021

Conditions
Sickle Cell Disease
Interventions
PROCEDURE

Bone Marrow Transplant (BMT)

Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.

DRUG

Hydroxyurea

Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.

DRUG

Thiotepa

Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.

DRUG

Fludarabine monophosphate

Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.

DRUG

Cyclophosphamide

"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."

OTHER

Rabbit Anti-thymocyte Globulin

Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).

RADIATION

Total Body Irradiation

Participants will receive 200 cGy of TBI in a single fraction.

Trial Locations (1)

30033

Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT02757885 - Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow | Biotech Hunter | Biotech Hunter